Tags

Type your tag names separated by a space and hit enter

Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways.
J Surg Res. 2013 Aug; 183(2):827-34.JS

Abstract

BACKGROUND

Remifentanil protects against ischemia/reperfusion (I/R)-induced organ injury, although its underlying mechanism remains elusive. This study was designed to examine the protective effect of remifentanil preconditioning, if any, against hepatic I/R injury in rats and the underlying mechanism involved.

MATERIALS AND METHODS

Adult Sprague-Dawley rats were randomly divided into sham operation (S group), ischemia/reperfusion (I/R group), and remifentanil preconditioning (R group) groups. Rats in the I/R group were subjected to a partial (70%) hepatic ischemia for 45 min, followed by 1 h, 3 h, and 6 h of reperfusion. Rats in the R group received venous injection of remifentanil (2 μg/kg/min) from 30 min prior to hepatic ischemia to the end of ischemia. Hepatic morphology and apoptosis were examined. Markers of liver damage, oxidative stress, and inflammation were evaluated. Mitochondrial function was assessed using mitochondrial membrane potential and appearance of mitochondrial swelling.

RESULTS

Compared with the S group, rats in the I/R group displayed a massive degenerative death in liver tissues and significantly enhanced cell apoptosis. Remifentanil preconditioning significantly reduced I/R-induced hepatocyte apoptosis. In addition, remifentanil protected against I/R-induced mitochondrial swelling and loss of membrane potential. Remifentanil preconditioning inhibited I/R-induced increases in tumor necrosis factor α, intercellular adhesion molecule 1, and nuclear factor κB p65 levels in liver tissues. Remifentanil preconditioning also inhibited the loss in superoxide dismutase and rise in malondialdehyde levels in liver tissues going through I/R injury.

CONCLUSIONS

Our data revealed that remifentanil preconditioning may turn on multiple cellular pathways in hepatocytes to protect the liver from I/R injury by alleviating hepatic apoptosis.

Authors+Show Affiliations

Department of Anesthesiology, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23608616

Citation

Zhao, Ge, et al. "Remifentanil Protects Liver Against Ischemia/reperfusion Injury Through Activation of Anti-apoptotic Pathways." The Journal of Surgical Research, vol. 183, no. 2, 2013, pp. 827-34.
Zhao G, Shen X, Nan H, et al. Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways. J Surg Res. 2013;183(2):827-34.
Zhao, G., Shen, X., Nan, H., Yan, L., Zhao, H., Yu, J., & Lv, Y. (2013). Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways. The Journal of Surgical Research, 183(2), 827-34. https://doi.org/10.1016/j.jss.2013.02.058
Zhao G, et al. Remifentanil Protects Liver Against Ischemia/reperfusion Injury Through Activation of Anti-apoptotic Pathways. J Surg Res. 2013;183(2):827-34. PubMed PMID: 23608616.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways. AU - Zhao,Ge, AU - Shen,Xin, AU - Nan,Haiyan, AU - Yan,Linfeng, AU - Zhao,Haikang, AU - Yu,Jun, AU - Lv,Yi, Y1 - 2013/03/22/ PY - 2012/11/30/received PY - 2013/02/21/revised PY - 2013/02/28/accepted PY - 2013/4/24/entrez PY - 2013/4/24/pubmed PY - 2013/10/18/medline KW - Apoptosis KW - Ischemia/reperfusion KW - Remifentanil SP - 827 EP - 34 JF - The Journal of surgical research JO - J Surg Res VL - 183 IS - 2 N2 - BACKGROUND: Remifentanil protects against ischemia/reperfusion (I/R)-induced organ injury, although its underlying mechanism remains elusive. This study was designed to examine the protective effect of remifentanil preconditioning, if any, against hepatic I/R injury in rats and the underlying mechanism involved. MATERIALS AND METHODS: Adult Sprague-Dawley rats were randomly divided into sham operation (S group), ischemia/reperfusion (I/R group), and remifentanil preconditioning (R group) groups. Rats in the I/R group were subjected to a partial (70%) hepatic ischemia for 45 min, followed by 1 h, 3 h, and 6 h of reperfusion. Rats in the R group received venous injection of remifentanil (2 μg/kg/min) from 30 min prior to hepatic ischemia to the end of ischemia. Hepatic morphology and apoptosis were examined. Markers of liver damage, oxidative stress, and inflammation were evaluated. Mitochondrial function was assessed using mitochondrial membrane potential and appearance of mitochondrial swelling. RESULTS: Compared with the S group, rats in the I/R group displayed a massive degenerative death in liver tissues and significantly enhanced cell apoptosis. Remifentanil preconditioning significantly reduced I/R-induced hepatocyte apoptosis. In addition, remifentanil protected against I/R-induced mitochondrial swelling and loss of membrane potential. Remifentanil preconditioning inhibited I/R-induced increases in tumor necrosis factor α, intercellular adhesion molecule 1, and nuclear factor κB p65 levels in liver tissues. Remifentanil preconditioning also inhibited the loss in superoxide dismutase and rise in malondialdehyde levels in liver tissues going through I/R injury. CONCLUSIONS: Our data revealed that remifentanil preconditioning may turn on multiple cellular pathways in hepatocytes to protect the liver from I/R injury by alleviating hepatic apoptosis. SN - 1095-8673 UR - https://www.unboundmedicine.com/medline/citation/23608616/Remifentanil_protects_liver_against_ischemia/reperfusion_injury_through_activation_of_anti_apoptotic_pathways_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-4804(13)00196-0 DB - PRIME DP - Unbound Medicine ER -